Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.53 |
| ▸ | ADRB3 known ✓ | P13945 | 6/20 | 0.51 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.51 |
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.51 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048311 | 0.98 | SLC6A3 (0.55) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6320255 | 0.98 | SLC6A3 (0.55) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL14126604 | 0.97 | HIF1A (0.54) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL23367359 | 0.82 | SMN1; SMN2 (0.52) | SLC6A3SLC6A2SLC6A4ADRB3ADRB1 | |
| SCHEMBL10886485 | 0.81 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL30488152 | 0.81 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL25272115 | 0.81 | ADRB1 (0.56) | CYP3A4CYP2D6ADRB3ADRB1HIF1A | |
| SCHEMBL23384857 | 0.80 | ADRB3 (0.46) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16198513 | 0.80 | HTR2A (0.50) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16198555 | 0.80 | HTR2A (0.50) | SLC6A3CYP3A4CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004022567-A1 | HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | SLC6A3 3291/4885SLC6A2 4331/4885SLC6A4 2199/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | SLC6A3 742/4885SLC6A2 1762/4885SLC6A4 589/4885 |
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | SLC6A3 731/4885SLC6A2 1184/4885SLC6A4 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.